FindTrial
Sign In

chimeric antigen receptor T cells

BIOLOGICAL3 trials

Sponsors

Zhujiang Hospital, Xuanwu Hospital, Beijing, The First Affiliated Hospital with Nanjing Medical University

Conditions

GliomaLeukemia, Acute Lymphocytic (ALL)Leukemia, Acute Myelogenous (AML)Leukemia, B-cellLymphoma, B-CellMalignant Glioma of BrainMyelodysplastic SyndromesRecurrence Tumor

Phase 1

CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
RecruitingNCT03291444
Zhujiang HospitalLeukemia, Acute Lymphocytic (ALL), Leukemia, Acute Myelogenous (AML), Myelodysplastic Syndromes
Start: 2018-05-05End: 2025-06-01Target: 30Updated: 2024-03-15
Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas
NCT03423992
Xuanwu Hospital, BeijingGlioma, Malignant Glioma of Brain, Recurrence Tumor
Start: 2018-03-02End: 2023-01-30Target: 100Updated: 2021-06-15

Phase 2

XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects
NCT03598179
The First Affiliated Hospital with Nanjing Medical UniversityLeukemia, B-cell, Lymphoma, B-Cell
Start: 2018-06-01End: 2020-07-01Target: 10Updated: 2019-08-07

Related Papers

Dendritic Cell Vaccines Extend CD19 CAR-T Cell Persistence and Improve the Outcomes in Refractory/Relapsed Adult B-ALL
Blood2023-11-023 citations
Combined cytotoxic and immune-stimulatory gene therapy using Ad-TK and Ad-Flt3L: Translational developments from rodents to glioma patients.
2023-08-1214 citations
First-in-Human Trial of EphA2-Redirected CAR T-Cells in Patients With Recurrent Glioblastoma: A Preliminary Report of Three Cases at the Starting Dose.
2021-06-2175 citations
THE ROLES OF PET/CT IN PREDICTING THE PROGNOSIS OF CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY TREATED PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA
Hematological Oncology2019-06-011 citations